HDT Bio
Latest round
- Seed
Last raised
- Oct 2020
Total raised
- $3M
Investors
- 1
About HDT Bio
Founded in 2018 and headquartered in Seattle, US, HDT Bio Corp is dedicated to advancing RNA vaccine technologies. The company has shifted strategies to enhance its vaccine development capabilities. The founding team includes Andre Lieber, Christopher Pirie, Darrick Carter, Neal Mody, and Steven Reed, with Steven Reed currently serving as CEO.9 mn received on May 17, 2021, from The National Institutes of Health.HDT Bio specializes in advanced RNA vaccine products designed to prevent and treat infectious diseases and cancers, utilizing its proprietary LION™ technology. The company’s core offerings include self-amplifying RNA (repRNA) vaccines, which leverage the immune system's capabilities to enhance effectiveness against challenging medical conditions. These vaccines are particularly aimed at improving patient outcomes and addressing unmet medical needs in areas such as malaria and enterovirus-D68. HDT Bio serves a diverse client base, focusing on partnerships with clinical-stage vaccine companies like MalarVx, which recently licensed HDT's LION™ platform for malaria vaccine development.HDT Bio's revenue structure is primarily based on licensing agreements and partnerships with other organizations engaged in vaccine development. The company collaborates with entities like MalarVx, facilitating the use of its LION™ technology and repRNA platform in the creation of new vaccines. These transactions typically involve licensing fees and potential milestone payments as product development progresses. While specific pricing plans for individual products or services are not publicly detailed, the collaboration model implies a B2B transaction framework, where costs are determined through negotiated agreements between HDT Bio and its partners.HDT Bio Corp.9 mn received from The National Institute of Allergy and Infectious Diseases to develop an HIV-1 RNA vaccine using its proprietary Lipid InOrganic Nanoparticle (LION) delivery system. The company aims to expand its product offerings and increase its market presence in the coming years, focusing on addressing critical health challenges and enhancing global vaccine accessibility.
Who invested in HDT Bio
1 investor across 1 round
See all investors in HDT Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Oct 5, 2020
Amount
$3M
Investors
Questions about HDT Bio
Who invested in HDT Bio?
HDT Bio has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HDT Bio raised?
HDT Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did HDT Bio last raise money?
HDT Bio's most recent round on record is a Seed, in Oct 2020.
What does HDT Bio do?
Founded in 2018 and headquartered in Seattle, US, HDT Bio Corp is dedicated to advancing RNA vaccine technologies.
Where is HDT Bio headquartered?
HDT Bio is headquartered in Seattle, US.
Which VCs invest in companies like HDT Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at HDT Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like HDT Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.